Navigation Links
Regulatory Affairs: The Key to Russia, New Life Science Webinar Hosted by Xtalks
Date:3/20/2013

Toronto, Canada (PRWEB) March 20, 2013

The regulatory environment in Russia changes rapidly – new clinical trial regulations and restrictions are introduced almost every quarter.

Our panel of leading Russian industry and government experts will help you navigate successfully through the sea of changes. Don’t miss this unique opportunity to interact with one of the co-authors of new amendments to the Russian Federal Law on Circulation of Drugs.

This webinar will include three insightful presentations:

  •     Dr. Yuri Afonchikov, Synergy’s VP for Regulatory Affairs, will discuss the Russian regulatory system through the eyes of a European expert
  •     Dr. Sergei Glagolev, one of the leading experts of the Federal Service on Surveillance in Healthcare (Roszdravnadzor) will discuss biosimiliars, pharmacovigilance and legal amendments in Russia
  •     Mr. Igor Stefanov, Synergy’s General Manager and a proponent of openness and transparency in the Russian CRO business, will analyze the current state of the clinical trial market in Russia and review the upcoming 2013 trends as well as historical data

For more information about this event or to register, visit: http://xtks.in/xto579-event.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
2. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
3. ADVENTRX Announces Establishment of Regulatory Advisory Board
4. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
5. Healthcare, Regulatory and Reimbursement Landscape - Australia
6. Northwest Bio Receives Regulatory Approval To Proceed With Its Phase III Trial In The UK
7. Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee
8. RAPS, Eucomed Partner to Provide Online Training to Regulatory Professionals Throughout Europe
9. Webinar on Clinical, Regulatory and Commercialization Strategies for Rare Diseases
10. Webinar to Discuss Biosimilar Regulatory Guidelines in India and Emerging Markets
11. Global Regulatory Milestones for Invibio Biomaterial Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  BioSpecifics Technologies ... company developing first in class collagenase-based products marketed ... CCH) in the U.S. and XIAPEX ® ... results from a randomized, double-blind Phase 2a study ... or edematous fibrosclerotic panniculopathy. The results showed that ...
(Date:8/21/2014)... , August 21, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... hormone therapy, is a means of replacing ... by the body. This type of therapy ...
(Date:8/21/2014)... YORK , Aug. 21, 2014 Mathematic studies ... Harvard University , and funded by the Jeffrey ... cells within tumors can be visually identified for elimination. These ... growth. The study, which shows a topological map of what ... time in cancer research, for while tumor cells can be ...
(Date:8/21/2014)... August 21, 2014 Ontotext S4 ... by Ontotext . Now the same enterprise ... of structured and unstructured data is available to start-ups ... of enterprise technology. Organizations that do not have resources ... management can use S4 since there is no need ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
... ... , ... (Vocus) February 4, 2010 -- Qteros, Inc. , a leading developer of second-generation ... announced today that Mick Sawka has joined the company as Vice President, Business Development, ...
... PARK, N.C. , Feb. 4 ... antiviral therapeutics, announced today that Gwendolyn Powell Painter , ...   , Dr. Painter has more than 20 years of ... clinical safety and pharmacovigilance, and occupational and environmental medicine.  In ...
... Mass. , Feb. 4 Interleukin Genetics, Inc. (NYSE Amex: ... at the 2010 BIO CEO & Investor Conference. The 12th Annual BIO ... the Waldorf-Astoria in New York . , Interleukin Genetics Chief Executive ... Company and discuss recent milestones at 1:00 p.m. ET in ...
Cached Biology Technology:Biofuels Technology Leader Qteros Names Mick Sawka Vice President, Business Development 2Biofuels Technology Leader Qteros Names Mick Sawka Vice President, Business Development 3Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer 2Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer 3Interleukin Genetics to Present at the 12th Annual BIO CEO Conference 2
(Date:8/22/2014)... (Edmonton) Thanks to important discoveries in basic and ... cancer has mobilized into a complex offensive spanning ... of Alberta chemistry lab could help find new ... developed a compound that targets a specific enzyme ... activity in cells from brain tumours. , Chemistry ...
(Date:8/22/2014)... is a multifunctional enzyme that localizes ... neuroprotective and cholesterol-synthesizing activities. DHCR24 overexpression ... amyloid β deposition. Dr. Xiuli Lu ... China constructed two recombinant adenoviruses (Ad-rSYN1-DHCR24-myc ... specifically in neuronal cells. They also ...
(Date:8/21/2014)... a significant reduction in smog-producing toxins in past ... A new study shows that while the Greater ... the toxins that contribute to smog, the city ... air pollution., Smog, which can cause or aggravate ... bronchitis, is produced by a set of complex ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2
... largest study of migraines, researchers have found 5 genetic regions ... onset of migraine. This study opens new doors to understanding ... The team identified 12 genetic regions associated with migraine susceptibility. ... known to play a role in controlling brain circuitries and ...
... study shows that the predator-prey relationship can affect the ... influence on the environment may offer a new way ... climate change. The study, conducted by researchers ... comes out this week in the Proceedings of ...
... - 250 million years ago, a mammal forerunner and ... Africa, Australia and France have discovered a world first ... burrow from the Karoo Basin of South Africa. ... and fossilized after being trapped by a flash flood ...
Cached Biology News:Getting to grips with migraine 2New study shows predators affect the carbon cycle 2Oddest couple ever found 2Oddest couple ever found 3Oddest couple ever found 4
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
Biology Products: